Ana Pena, PhD,  —

Two federal grants totaling $6.1 million were awarded to Vanderbilt University Medical Center (VUMC) and the Translational Genomics Research Institute (TGen) to investigate the molecular origin of idiopathic pulmonary fibrosis (IPF), as well as of other forms of pulmonary fibrosis (PF). The first is a $3.5-million five-year…

Saracatinib (AZD0530), an investigational oral therapy under development by AstraZeneca, was granted Orphan Drug Designation as a potential treatment for idiopathic pulmonary fibrosis (IPF) by the U.S. Food and Drug…

Exposure to silica dust may trigger pulmonary fibrosis (PF) because silica particles block a self-cleansing process used by cells, termed autophagy, which drives cell death in the lungs, a study using both human cells and mice showed.  Researchers say the findings may improve…

The Envisia Genomic Classifier, Veracyte‘s genomic test for improved diagnosis of idiopathic pulmonary fibrosis (IPF),  was granted full U.S. coverage by Medicare. The coverage…

The U.S. Food and Drug Administration (FDA) has cleared the way for X-Rx’s idiopathic pulmonary fibrosis (IPF) therapy candidate X-165 to move into the first clinical tests.  The FDA approved X-Rx’s…

One year of treatment with Genentech‘s Esbriet (pirfenidone) significantly reduced the incidence of disease progression events — including decline in lung function and physical capacity, respiratory-related hospitalizations, and death — in people with idiopathic pulmonary fibrosis…

Panobinostat, an approved treatment for multiple myeloma, exerts anti-fibrotic activity, inducing cell death and reducing the proliferation of lab-grown fibroblasts from idiopathic pulmonary fibrosis (IPF) patients, a preclinical study reports. The data also suggest that, despite an ability to inhibit cellular pathways involved in fibrosis, approved IPF…

RXC006, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF) and other types of fibrosis, was seen to ease lung scarring in a mouse model of IPF, its developer, Redx Pharma, has announced. The investigative inhibitor is also reported to work favorably in human lung fibroblasts grown in the laboratory.

A herbal extract derived from a product used in Korean traditional medicine may be a potential alternative treatment for idiopathic pulmonary fibrosis (IPF), a mouse study suggests. The herbal extract was found to reduce inflammation and markers of lung fibrosis in a mouse model of PF…

Researchers have uncovered an immunological mechanism that underlies fibrosis in different lung conditions, including sarcoidosis and idiopathic pulmonary fibrosis (IPF), a study reports. In mouse models of pulmonary fibrosis (PF), the study also demonstrated…